The lambda variant of the virus responsible for Govit-19 is now available in 29 countries. The World Health Organization (WHO) has called this a “variation of interest.” Here we know about him.
The Peru The country with the highest number of deaths so far Govit-19 To a resident. The disease causes 596 deaths per 100,000 people. This number is almost twice as high as the second most affected country Hungary, Which records 307 deaths per 100,000 population.
Several factors explain Peru’s health condition: poor financial and inadequately prepared health care system, including very few intensive care facilities, poorly funded and adequately prepared health care system, very low intensive care beds, slow use of vaccines, limited testing ability. Large informal economy (large number of people unable to work), crowded houses …
Also read: Here’s why corona virus types have new names
Moreover, the country is also facing the Lambda variation. First in the capital, Lima, in August 2020 and April 2021, 97% of all corona virus cases analyzed in Peru were represented.
Currently around the world
This lambda variant is now found worldwide. According to the latest report of the World Health Organization (WHO) from 15 June 2021, it has been identified in 29 countries.
In particular, you can read about the Lambda variant in this document “In many countries it is associated with significant rates of social spread, increasing over time, and the incidence of Govt-19 is increasing.”
On June 14, 2021, the WHO announced the Lampta variant as a variant of interest. Public Health England, the British public health agency, followed suit on June 23, naming it a “variation under investigation” because of its global expansion and many significant mutations.
Variation of interest is a contagious virus that is contagious (how easily the virus spreads), the severity of the disease, the ability to escape immunity provided by a previous infection or vaccine, or the possibility of avoiding diagnostic tests.
The “Extraordinary Admission” Many scientists fear that the mutations caused by the lambda variant may be more contagious. The spike (or S) protein of the lambda variant actually has seven mutations (for the record, spike protein, whose form is reminiscent of a fungus, is present in numerous copies on the outer shell of the virus. The ACE2 protein present in our cells allows the corona virus to invade them).
These mutations not only allow the lambda variant to bind easily to our cells, but also complicate the work of our antibodies by controlling their attachment to the variants, thus neutralizing it.
However, it should be remembered that neutralizing antibodies are not the only protective weapon of our immune system (but it is easy to read): D lymphocytes are involved in both the destruction of infected cells, the synthesis of the immune response, and the memorization of infections. Plays an important role. So a few mutations – which are unusual – may not be enough to allow the lambda variant to completely escape from our immune system.
Is it too dangerous?
Currently, there are only a few In advanceI.e., articles whose method and results have not yet been reviewed by other scientists (Peer Review). In other words, no study on the Lambda variant has actually been published.
One of which Pre-printing Presents results obtained by researchers at the Crossman School of Medicine at New York University in the United States. The purpose of this work was to verify the neutralizing ability of sera containing antibodies to vaccine-induced antibodies to spike protein viruses with the same mutations as the lambda variant.
Results show that these viruses have approximately 2.3 times more resistance to serum neutralization than patients vaccinated with the modern RNA vaccine, 3 times more resistance to neutralization by serum of patients vaccinated with the Pfizer vaccine, and 3.3 times more resistance. Neutralization by serum in patients with Govit-19 before the appearance of lambda.
It should be emphasized, however, that this is not a massive reduction in the effectiveness of neutralizing antibodies. The researchers also conclude that their results suggest that the currently used vaccines are safe from the lambda variant.
Researchers at the University of Chile have studied the Sinovac vaccine (also known as coronavac) against the Lampta variant. They also observed a three reduction in the effectiveness of neutralizing vaccine-induced antibodies against this variant compared to the original virus.
These two studies have confirmed that the neutralization of antibodies is at least partially preserved, especially since this is only one aspect of the immune response induced by the vaccine. Currently, of the eight confirmed cases of lambda variation in the UK, most are linked to overseas travel.
According to Public Health UK’s latest risk assessment report dated July 8, the lambda variant has not yet replaced the delta variant in any of the countries where both types are in circulation (but authors emphasize the need to carefully monitor the epidemiological situation in Peru and Chile). Other studies are ongoing, however, for now, the Lampta variant is a “variant of interest”, not a “variant of concern”.